Baird lowers Cava Group stock price target to $95 from $115 on Q2 comps

CAVA Group Inc. reported second-quarter 2025 earnings that surpassed revenue and EPS expectations, yet disappointing comparable sales growth led to mixed analyst reactions and multiple price target reductions. While firms like Baird, Jefferies, and KeyBanc lowered their targets citing slower same-store sales, they, along with Stifel, largely maintained positive long-term outlooks, emphasizing strong overall financial performance, improved margins, robust new unit economics, and a belief that comparable sales weakness is temporary or macro-driven. This divergence highlights a debate among analysts regarding the significance of comparable sales versus broader financial health and growth trajectory for the Mediterranean fast-casual chain.

Analysis

CAVA Group Inc. presented a dichotomous second-quarter 2025 report, beating consensus estimates on both revenue ($278.2 million vs. $249.66 million expected) and EPS ($0.16 vs. $0.14 expected), yet delivering a disappointing 2.1% growth in comparable sales. This sales miss prompted several analyst firms, including Baird, Jefferies, and KeyBanc, to reduce their price targets to $95, $100, and $85, respectively, citing the slower growth. However, the overarching sentiment from analysts remains constructive, with firms largely maintaining 'Buy' or 'Outperform' ratings. The consensus view attributes the weak comparable sales to transient macroeconomic headwinds and challenging year-over-year comparisons rather than a fundamental deterioration of the brand. This long-term optimism is supported by several factors: strong underlying fundamentals including a 32% trailing-twelve-month revenue growth rate and a healthy current ratio of 3.0; an EBITDA beat driven by improved margins and lower expenses; the 'very strong' performance of new restaurant units; and Baird's observation that comparable sales have already returned to healthier levels in early Q3. The divergence in analyst actions, particularly Stifel maintaining its $125 price target while questioning the market's reaction, highlights a key debate over whether the near-term sales deceleration warrants the stock's pullback.

Key Decisions for Investors

• Investors should evaluate whether the stock's recent decline, driven by the comparable sales miss, presents a buying opportunity, aligning with Baird's recommendation to accumulate shares on weakness given the otherwise strong financial results.
• Monitor upcoming quarterly reports for sustained momentum in comparable sales, as a continued recovery would validate the thesis that the Q2 slowdown was a temporary, macro-driven event and that the core growth story remains intact.
• Consider the significant divergence in analyst price targets ($85 to $125) as an indicator of the current debate between near-term sales concerns and the company's long-term potential fueled by new unit expansion and margin improvements.